Latest diabetic neuropathy Stories
Monitoring blood fat levels as closely as blood sugar may help stem diabetic neuropathy, U.S. researchers suggest.
Data shows 82% of patients have neuropathy onset during their 30s-60s NEW YORK, May 13 /PRNewswire-USNewswire/ -- A new national Neuropathy Association poll of peripheral neuropathy patients finds that the majority of respondents had their neurological disease begin during their prime adult years, with 82% experiencing neuropathy's onset between the ages of 30-69.
Conference Call Scheduled Today at 4:30pm ET European Commission Decision on Qutenza(TM) Expected in 1H 2009 Company to Provide Update on FDA review of Qutenza During Conference Call Today Corporate Highlights: - CHMP issued positive opinion recommending approval of Qutenza(TM) (formerly NGX-4010) for treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain Upcoming 2009 Milestones: - European Commission...
-Clinical Data Presented at American Pain Society Annual Meeting- BALTIMORE, May 7 /PRNewswire/ -- Arcion Therapeutics, Inc., a venture backed clinical stage biotechnology company that develops pain therapies, today announced the presentation of data demonstrating that its lead candidate, ARC-4558, significantly reduced pain caused by diabetic neuropathy in a double-blind, placebo-controlled trial.
MONTREAL, May 6 /PRNewswire/ - Aegera Therapeutics is pleased to announce the initiation of a Phase 2a, proof-of-concept, clinical trial for AEG33773, a novel, orally bio-available small molecule therapeutic addressing the under-served market of painful diabetic neuropathy. The Phase 2a study, entitled A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of AEG33773 versus Placebo in Patients with Painful Diabetic Peripheral Neuropathy will...
DOYLESTOWN, Pa., May 1 /PRNewswire-FirstCall/ -- The Quigley Corporation, (Nasdaq: QGLY) www.quigleyco.com today reported net sales of $4.0 million, for the first quarter ended March 31, 2009, compared to $5.3 million reported for the same period in 2008. The decrease in net sales for the first quarter of 2009 reflects a market-wide decrease in consumer purchases of cold remedy products as reported by Information Resources Inc., ("IRI") data, general economic weakness and lower incidence of...
SAN MATEO, Calif., April 30 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced it will hold a conference call on Thursday, May 7, 2009 at 4:30 p.m. ET (1:30 p.m.
DOYLESTOWN, Pa., April 30 /PRNewswire-FirstCall/ -- Quigley Pharma Inc., www.quigleyco.com, a wholly-owned subsidiary of The Quigley Corporation (Nasdaq: QGLY) announced today that their recently completed Phase 2 double-blinded, placebo-controlled, clinical trial of diabetic peripheral neuropathy, demonstrated a significant improvement in two key measures of distal sensory nerve function in the group treated with QR333.
Evaluation of Neurologic Safety following Treatment with Qutenza(TM) (NGX-4010) Identification of Impact of PHN and PDN on Health Care Costs SAN MATEO, Calif., April 29 /PRNewswire-FirstCall/ -- NeurogesX, Inc.
Qutenza(TM) Receives Positive Committee Recommendation in European Union Corporate Highlights: - CHMP issued positive opinion recommending approval of Qutenza(TM) (formerly NGX-4010) for treatment of peripheral neuropathic pain in non-diabetic adults either alone or in combination with other medicinal products for pain - Qutenza NDA accepted for review by U.S.
- Small missiles, especially grape, canister, fragments of iron, and the like, when fired, as upon an enemy at close quarters.
- To fire mitraille at.